The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Principal Rapamycin-Sensitive p70s6k Phosphorylation Sites, T-229 and T-389, Are Differentially Regulated by Rapamycin-Insensitive Kinase Kinases
Open accessAbstract
Mitogen-induced activation of p70(s6k) is associated with the phosphorylation of specific sites which are negatively affected by the immunosuppressant rapamycin, the fungal metabolite wortmannin, and the methylxanthine SQ20006. Recent reports have focused on the role of the amino terminus of the p85(s6k) isoform in mediating kinase activity, with the observation that amino-terminal truncation mutants are activated in the presence of rapamycin while retaining their sensitivity to wortmannin. Here we show that the effects of previously described amino- and carboxy-terminal truncations on kinase activity are ultimately reflected in the phosphorylation state of the enzyme. Mutation of the principal rapamycin-targeted phosphorylation site, T-389, to an acidic residue generates a form of the kinase which is as resistant to wortmannin or SQ20006 as it is to rapamycin, consistent with the previous observation that T-389 was a common target of all three inhibitors. Truncation of the first 54 residues of the amino terminus blocks the serum-induced phosphorylation of three rapamycin-sensitive sites, T-229 in the activation loop and T-389 and S-404 in the linker region. This correlates with a severe reduction in the ability of the kinase to be activated by serum. However, loss of mitogen activation conferred by the removal of the amino terminus is reversed by additional truncation of the carboxy-terminal domain, with the resulting mutant demonstrating phosphorylation of the remaining two rapamycin-sensitive sites, T-229 and T-389. In this double-truncation mutant, phosphorylation of T-229 occurs in the basal state, whereas mitogen stimulation is required to induce acute upregulation of T-389 phosphorylation. The phosphorylation of both sites proceeds unimpaired in the presence of rapamycin, indicating that the kinases responsible for the phosphorylation of these sites are not inhibited by the macrolide. In contrast, activation of the double-truncation mutant is blocked in the presence of wortmannin or SQ20006, and these agents completely block the phosphorylation of T-389 while having only a marginal effect on T-229 phosphorylation. When the T-389 site is mutated to an acidic residue in the double-truncation background, the activation of the resulting mutant is insensitive to the wortmannin and SQ20006 block, but interestingly, the mutant is activated to a significantly greater level than a control in the presence of rapamycin. These data are consistent with the hypothesis that T-389 is the principal regulatory phosphorylation site, which, in combination with hyperphosphorylation of the autoinhibitory domain S/TP sites, is acutely regulated by external effectors, whereas T-229 phosphorylation is regulated primarily by internal mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hibi, M., Lin, A., Smeal, T., Minden, A., & Karin, M. (1993) · Genes & Development · doi:10.1101/gad.7.11.2135 · Cited by 1,886
Cited by
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
Hara, K., Yonezawa, K., Weng, Q.-P., Kozlowski, M. T., Belham, C., & Avruch, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14484 · Cited by 1,367
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,138
Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2
Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043
Self-citationRegulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.12.3693 · Cited by 934
Self-citationPhosphorylation and Activation of p70 s6k by PDK1
Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., & Thomas, G. (1998) · Science · doi:10.1126/science.279.5351.707 · Cited by 826
Self-citationThe mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Chan, T. O., Rittenhouse, S. E., & Tsichlis, P. N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.965 · Cited by 737
Baar, K., & Esser, K. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.276.1.c120 · Cited by 726
Ribosomal S6 Kinase Signaling and the Control of Translation
Dufner, A., & Thomas, G. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4683 · Cited by 676
Self-citationDisruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase
Shima, H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6649 · Cited by 636
The target of rapamycin (TOR) proteins
Raught, B., Gingras, A.-C., & Sonenberg, N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121145898 · Cited by 605
Alessi, D. R., Kozlowski, M. T., Weng, Q.-P., Morrice, N., & Avruch, J. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70037-5 · Cited by 574
The modular phosphorylation and activation of p70s6k
Pullen, N., & Thomas, G. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00323-2 · Cited by 540
Self-citationPeterson, R. T., Desai, B. N., Hardwick, J. S., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4438 · Cited by 486
Identification of a Conserved Motif Required for mTOR Signaling
Schalm, S. S., & Blenis, J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00762-5 · Cited by 482
Scott, P. H., Brunn, G. J., Kohn, A. D., Roth, R. A., & Lawrence, J. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7772 · Cited by 479
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases
Raught, B., Peiretti, F., Gingras, A., Livingstone, M., Shahbazian, D., Mayeur, G. L., Polakiewicz, R. D., Sonenberg, N., & Hershey, J. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600193 · Cited by 473
TOR signalling and control of cell growth
Thomas, G., & Hall, M. N. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80078-6 · Cited by 462
Self-citationGenetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin
Oldham, S., Montagne, J., Radimerski, T., Thomas, G., & Hafen, E. (2000) · Genes & Development · doi:10.1101/gad.845700 · Cited by 429
Self-citationTzatsos, A., & Kandror, K. V. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.63-76.2006 · Cited by 399
Regulation of the p70 S6 Kinase by Phosphorylation in Vivo
Weng, Q.-P., Kozlowski, M., Belham, C., Zhang, A., Comb, M. J., & Avruch, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16621 · Cited by 375
Kimura, N., Tokunaga, C., Dalal, S., Richardson, C., Yoshino, K., Hara, K., Kemp, B. E., Witters, L. A., Mimura, O., & Yonezawa, K. (2003) · Genes to Cells · doi:10.1046/j.1365-2443.2003.00615.x · Cited by 372
Translational Control in Cancer Etiology
Ruggero, D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012336 · Cited by 367
Insulin signal transduction through protein kinase cascades
Avruch, J. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006823109415 · Cited by 365
Elucidating TOR Signaling and Rapamycin Action: Lessons from Saccharomyces cerevisiae
Crespo, J. L., & Hall, M. N. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.4.579-591.2002 · Cited by 365
Peterson, R. T., Beal, P. A., Comb, M. J., & Schreiber, S. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7416 · Cited by 339
Chan, A. Y. M., Soltys, C.-L. M., Young, M. E., Proud, C. G., & Dyck, J. R. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403528200 · Cited by 331
Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis
RUTTER, G. A., da SILVA XAVIER, G., & LECLERC, I. (2003) · Biochemical Journal · doi:10.1042/bj20030048 · Cited by 328
4E-BP1 and S6K1: translational integration sites for nutritional and hormonal information in muscle
Shah, O. J., Anthony, J. C., Kimball, S. R., & Jefferson, L. S. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.4.e715 · Cited by 286
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation
Dennis, P. B., Fumagalli, S., & Thomas, G. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80007-0 · Cited by 275
Self-citationRaught, B. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.434 · Cited by 270
Molecular mechanisms for the control of translation by insulin
PROUD, G. C., & DENTON, M. R. (1997) · Biochemical Journal · doi:10.1042/bj3280329 · Cited by 257
HORNBERGER, T. A., STUPPARD, R., CONLEY, K. E., FEDELE, M. J., FIOROTTO, M. L., CHIN, E. R., & ESSER, K. A. (2004) · Biochemical Journal · doi:10.1042/bj20040274 · Cited by 256
Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells
Beevers, C. S., Li, F., Liu, L., & Huang, S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21932 · Cited by 256
Jastrzebski, K., Hannan, K. M., Tchoubrieva, E. B., Hannan, R. D., & Pearson, R. B. (2007) · Growth Factors · doi:10.1080/08977190701779101 · Cited by 240
“…being a rapamycin resistant kinase, phosphorylation of T229 is abolished by treatment with this inhibitor, indicating a requirement for prior phosphorylation of T389 which perhaps forms a docking site for PDK1 and can thus lead to maximal kinase activation (Dennis et al. 1996; Moser et al. 1997).”
BackgroundResveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt
Chan, A. Y. M., Dolinsky, V. W., Soltys, C.-L. M., Viollet, B., Baksh, S., Light, P. E., & Dyck, J. R. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802869200 · Cited by 244
Koopman, R., Zorenc, A. H. G., Gransier, R. J. J., Cameron-Smith, D., & van Loon, L. J. C. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00530.2005 · Cited by 196
Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance
Liu, S.-C., Tsang, N.-M., Chiang, W.-C., Chang, K.-P., Hsueh, C., Liang, Y., Juang, J.-L., Chow, K.-P. N., & Chang, Y.-S. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63428 · Cited by 184
Role of mTORC1 in mechanically induced increases in translation and skeletal muscle mass
Goodman, C. A. (2019) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01011.2018 · Cited by 133
Tumour suppressors hamartin and tuberin: intracellular signalling
Krymskaya, V. P. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(03)00040-8 · Cited by 130
Christie, G. R., Hajduch, E., Hundal, H. S., Proud, C. G., & Taylor, P. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107694200 · Cited by 125
Song, X., Dilly, A.-K., Kim, S.-Y., Choudry, H. A., & Lee, Y. J. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.242 · Cited by 24
Metadata
- Authors
- Dennis, P. B., Pullen, N., Kozma, S. C., & Thomas, G.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1996-11-01
- Volume
- 16
- Issue
- 11
- Pages
- 6242-6251
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2135090837
- Cited by
- 248
- References
- 1
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.